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1. Introduction
A multidisciplinary approach, combining advances in
systemic chemotherapy, targeted agents and aided by
better surgical and imaging techniques has signiﬁcantly
enhanced the outcome for patients with metastatic
colorectal cancer (mCRC) over the last two decades
(Fig. 1). 1 Advancements in the management of un-
resectable mCRC have been characterised by small
incremental improvements in overall survival which
now extends beyond 2 years with the addition of
biological agents to standard ﬂuoropyrimidine-based
chemotherapy regimens. Today, a whole host of newly
identiﬁed targeted therapeutic agents inhibiting one or
more key pathways are being evaluated in phase III
clinical trials (including aﬂibercept and regorafenib) 2,3 as
potential new treatments for mCRC.
Our understanding of the beneﬁts of targeted agents
has been aided by large well-designed multicentre
studies in patients with proven chemorefractory mCRC.
While cetuximab initially showed only modest beneﬁts
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in overall survival in unselected patients (Hazard ratio
[HR], 0.77, 95%CI: 0.64–0.92), 4 a subsequent study
of patients with wild-type K-ras tumours revealed
that cetuximab plus best supportive care (BSC) was
associated with a doubling overall survival (median,
9.5 vs. 4.8 months for BSC alone; HR for death, 0.55;
P< 0.001) in chemorefractory disease. 5 In the same way,
the recent evaluation of regorafenib plus BSC showed
only a modest improvement in overall survival (median,
6.4 vs. 5.0 months for placebo plus BSC; HR, 0.77 [95%CI:
0.63–0.94; 1-sided P=0.0051]) in patients with mCRC
who progressed after standard therapies, 3 but there
is early evidence to suggest that some patients do
beneﬁt more than others. 3 Like locoregional treatments,
the challenge with targeted agents is to select the
cohorts of patients who will beneﬁt most. For targeted
agents such as regorafenib, the decision to treat is
likely to be based on the identiﬁcation of a combination
of molecular biomarkers (angiogenic signatures) for
regorafenib activity.
2. Locoregional treatment with SIRT
The published evidence suggests that locoregional
treatments may play a complementary role to systemic
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Fig. 1 – (a) Overall survival of mCRC increasing over the decades, with (b) progressively more complex regimens combined
with biologicals. Reproduced from Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer
is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009;27:3677−83 with permission
from American Society of Clinical Oncology.
Table 1 – Comparative or prospective studies of selective internal radiation therapy with 90Y resin microspheres
in chemorefractory colorectal cancer liver metastases
Investigators n Treatment ORR SD TTP/PFS* Survival P value HR
Hendlisz et al. 7 (cross-over at progression) 21 SIRT+ 5-FU 10% 76% 5.5/4.5 months 10.0 months 0.80 0.92
23 5-FU + salvage with
SIRT at PD
0% 35% 2.1 months 7.3 months
Seidensticker et al. 8 (matched-pairs) 29 SIRT 41% 17% 5.5 months* 8.3 months <0.001 0.26
29 Best supportive care nr nr 2.1 months* 3.5 months
Bester et al. 9 (retrospective comparison) 224 SIR-Spheres nr nr nr 11.9 months 0.001 0.50
29 Best supportive care nr nr nr 6.6 months
Cosimelli et al. 10 50 SIRT 24% 24% 4 months* 12.6 months
SIRT with 90Y resin microspheres; nr: not reported; PFS: Progression-free survival; TTP: Time to progression.
treatment by improving the local control of metastases
in the liver. Comparisons between these two treatment
modalities cannot be made because the locoregional
treatments are used to manage liver-limited or liver-
predominant disease while clinical trials of systemic
agents include a much broader group of patients
including those with disease that has progressed beyond
the liver to the lungs and peritoneum.
Early evidence for selective internal radiation ther-
apy (SIRT) in mCRC was largely based on small
case series. In review of the evidence in 2009, the
Cochrane group concluded that there was a need
for well-designed, adequately powered phase III trials
to assess the effect of SIRT combined with modern
chemotherapy regimens. 6 Further studies with SIRT
were also needed in chemorefractory disease, with a
particular focus on the impact on quality of life. 6
Since this review, four comparative or prospective
studies have been published on SIRT in chemorefractory
patients (Table 1). 7−10 One such study at the University
Hospitals Leuven in collaboration with other Belgian sites
evaluated 44 patients with liver-limited mCRC for whom
all other evidence-based treatments had failed. 7 Patients
were randomised to receive either protracted IV infusion
of 5-FU (300mg/m2 day 1−14 every 3 weeks) or SIRT using
90Y resin microspheres plus 5-FU (225mg/m2 [cycle 1]
then 300mg/m2 day 1−14 every 3 weeks, thereafter) until
documented hepatic progression. Most patients had a
good performance status (ECOG 0 or 1). The burden of
liver metastases was similar in both treatment arms.
The study found that median time to liver progression
was signiﬁcantly prolonged with the addition of SIRT
compared to 5-FU alone (5.5 vs. 2.1 months; hazard ratio
[HR] 0.38; p= 0.003). The median time to progression
at any site was also increased in the SIRT arm (4.5
vs. 2.1 months; HR 0.51; p=0.03), as was the disease
control rate (86% vs. 35%; p=0.001). After 10 of 23
patients on 5-FU monotherapy crossed over to receive
SIRT following progression, median overall survival was
7.3 and 10.0 months in the 5-FU and SIRT plus 5-FU
arms, respectively (HR=0.92 95%CI 0.47–1.78; p= 0.80).
Grade 3 or 4 toxicities were recorded in 6 patients
following 5-FU monotherapy and in 1 patient following
SIRT plus 5-FU treatment (p=0.10). Adverse events
associated with SIRT are generally mild and transient,
including nausea, fever and abdominal pain (Table 2).
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Table 2 – Adverse events proﬁle with SIRT using 90Y resin microspheres in chemorefractory colorectal
cancer liver metastases
AE Incidence Characteristics Prevention/Action
Fever >50% Mild (grade 1*) onset on day of treatment for up
to 1 week
None normally required
Abdominal pain ~50% (~10% grade 3−4) Acute onset during treatment; self-limiting
(normally <24h)
May require narcotic (>oral analgesia)
Nausea ~40% (<5% grade 3−4) Highest in treatment-experienced; self-limiting
(normally <24h)
Prophylactic anti-emetics
Fatigue ~40% (<5% grade 3−4) Onset in 1st month post-SIRT, normally
subsides within 2 weeks
Adequate nutrition and hydration;
prophylactic oral steroids
Abnormal Liver
Function Tests
~20−40% (1−6% grade 3−4) Particularly in combination with chemotherapy;
transient: resolves in days (ALT, AST), weeks
(bilirubin) or months (albumin)
None normally required
More rarely, radiation-associated gastrointestinal ulcers
can occur and these are more difﬁcult to treat. 11 Patients
should be carefully monitored with a low threshold of
suspicion for evidence of gastrointestinal ulcer to ensure
early and effective treatment, especially if subsequent
treatment with antiangiogenics such as bevacizumab is
being considered.
In summary, SIRT is likely to play an important
complementary role to systemic therapies for the control
of colorectal liver metastases. Ongoing randomised con-
trolled clinical trials with conventional chemotherapies
with or without SIRT (in the ﬁrst-line setting and in
chemorefractory disease) will further deﬁne the role of
this treatment modality in the management of liver-
dominant mCRC.
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